euro adhoc: Marseille-Kliniken AG
quarterly or semiannual financial statement
/ - Turnover increase to 54.9 million Euros in the first quarter of 2007/2008
- Above-average consolidated result increases from 2.0 million Euros to 7.0
million Euros
- Reha
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
3-month report
08.11.2007
Berlin, 8th November 2007. The Marseille-Kliniken AG, (Prime Standard, ISIN DE 0007783003, MKA) has been able to improve its results in an above-average way. In the first quarter of the current financial year (01.07.2007 - 30.09.2007) the company turnover increased to 54.9 million Euros (previous year: 52.8 million Euros). The net profit for the group by minority interests improved from 2.0 million Euros to 7.0 million Euros. Per share this is equal to a result of 0.57 Euros compared to 0.16 Euros in the previous year. The EBIT reached 4.3 million Euros after 4.0 million Euros in the previous year. The EBITDAR was at 15.7 million Euros with 0.3 million Euros above the previous year with 15.4 million Euros. The balanced net capital is 82.4 million Euros compared with 68.0 million Euros in the previous year, which is equivalent to an equity ratio of 28.5 % (previous year 20.9 %) of the balance sheet total.
The significant rise of the result primarily rests on two effects: on the one hand, the utilisation rate in the company improved from 89.7 % in the previous year to a current 92.3 % and on the other hand, the company profited from unique tax effects to the value of 4.9 million Euros due to the amended tax rates as part of the 2008 corporate tax reform.
The result adjusted in accordance with DVFA/SG (IFRS) totalled 4.8 million Euros in the financial year compared to 3.6 million Euros in the previous year. Per share this is equal to a result increase by 0.09 Euros to 0.39 Euros (previous year: 0.30 Euros). The EBITDAR was 16.8 million Euros (previous year: 16.4 million Euros) and the EBIT reached 6.6 million Euros (previous year: 6.2 million Euros).
Growth is constantly being pushed in the care division: the turnover increased by 2.7 million Euros to 43.0 million Euros compared to the previous year (previous year: 40.3 million Euros). By the deadline the capacity of care was further improved by 384 beds to 7,518 beds (previous year: 7,134 beds). The result in accordance with DVFA/SG (IFRS) was at 4.8 million Euros, 0.6 million Euros higher than in the previous year. The utilisation rate improved against the market trend by 1.2 % to 93.8 %.
In the rehabilitation sector the restructuring measures are taking hold. By the omission of a loss-making location from the books the capacity in this sector decreased from 1478 beds in the previous year to 1283 beds in the reporting interval. So the turnover in this sector was also reduced to 11.9 million Euros (previous year: 12.5 million Euros). The utilisation rate in rehabilitation had a positive effect, which improved from 77.8 % in the previous year by 9.1 % to 86.9 %. The DVFA result, which in the previous year was still -0.6 million Euros, was balanced out in the first quarter of 07/08. The overall bed capacity in the company increased due to the cutback in the rehabilitation segment and the expansion in the care sector from 8,612 beds to 8,801 beds.
For the entire financial year 07/08 the company is expecting a turnover of 240 million Euros, an EBIT of 24 million Euros and a result after tax of 18 million Euros. In the current business year three new houses with a total of 310 beds (in Potsdam, Schömberg and Düsseldorf) are being added to the network. Further locations are in the construction phase and also in the development of supervised housing further bed capacities will be created in the care segment.
End of the ad hoc release
end of announcement euro adhoc 08.11.2007 07:31:45
Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin
Germany
Tel.: +49-(0)30 / 246 32-400
Fax: +49-(0)30 / 246 32-401
www.marseille-kliniken.com
Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 320 279 10
Fax: +49-(0)40 / 320 279 114
www.hillermann-consulting.de
Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / official dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hamburg / official dealing
Original content of: Marseille-Kliniken AG, transmitted by news aktuell